Scarica l'app Stockscreener
25.33
0.00%
0.00
Dopo l'orario di chiusura:
25.32
-0.010
-0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.33
Aprire:
$25.32
Volume 24 ore:
33.97M
Relative Volume:
0.90
Capitalizzazione di mercato:
$144.37B
Reddito:
$63.32B
Utile/perdita netta:
$7.52B
Rapporto P/E:
19.42
EPS:
1.3043
Flusso di cassa netto:
$9.48B
1 W Prestazione:
-1.86%
1M Prestazione:
-8.09%
6M Prestazione:
-0.47%
1 anno Prestazione:
+10.95%
Intervallo 1D:
$25.19
$25.39
Intervallo di 1 settimana:
$25.19
$26.10
Portata 52W:
$22.64
$28.75
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.33 | 144.37B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
988.09 | 896.13B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.92 | 545.74B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
209.41 | 371.72B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
183.92 | 281.60B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
149.15 | 282.55B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | Argus | Hold → Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Underperform |
| 2026-02-20 | Iniziato | Barclays | Underweight |
| 2026-02-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer (NYSE: PFE) CEO receives 24 phantom stock units in deferred plan - Stock Titan
Target Upgraded, Pfizer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Arbor Biotechnologies Appoints Mathew Pletcher, Ph.D., as Chief Scientific Officer - GlobeNewswire Inc.
Why Pfizer Stock Still Looks Deeply Undervalued In 2026 (NYSE:PFE) - Seeking Alpha
Thrivent Financial for Lutherans Acquires 72,504 Shares of Pfizer Inc. $PFE - MarketBeat
214,779 Shares in Pfizer Inc. $PFE Purchased by North Dakota State Investment Board - MarketBeat
Daiwa Securities Adjusts Price Target on Pfizer to $28 From $27, Maintains Neutral Rating - marketscreener.com
Pfizer Inc. (NYSE:PFE) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
FY2026 EPS Estimates for Pfizer Lowered by Erste Group Bank - MarketBeat
Pfizer Inc. stock (US7170811035): Q1 earnings beat, higher 2026 guidance and rich dividend yield dra - AD HOC NEWS
Pfizer Inc. stock (US7170811035): Q1 earnings beat, higher 2026 guidance and rich dividend yield in - AD HOC NEWS
Pfizer Faces Busy Week After Friday’s Drop - TechStock²
Pfizer Inc. Trade Ideas — LS:852009 - TradingView
Seagen Inc (Acquired) stock (US8166361055): what remains after the Pfizer takeover - AD HOC NEWS
How Pfizer Comirnaty Works and Where It Fits Today - AD HOC NEWS
John G Ullman & Associates Inc. Has $5.13 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Stock Holdings Boosted by Canada Post Corp Registered Pension Plan - MarketBeat
Pfizer Inc. Trade Ideas — AQUISEU:PFED - TradingView
Pfizer Inc. Trade Ideas — BX:PFEUSD - TradingView
Pfizer Inc stock (US7170811035): new trial data and pipeline focus keep attention on the pharma gian - AD HOC NEWS
Wolfe Research Says COVID Uncertainty Continues to Weigh on Pfizer (PFE) Outlook - Insider Monkey
PFE Stock Quote Price and Forecast - CNN
Assessing Pfizer (PFE) Valuation After Recent Share Price Weakness And Oncology Growth Expectations - simplywall.st
Pfizer asks for emergency use of its coronavirus vaccine - The Indian Panorama
Pfizer (NYSE:PFE) Trading Down 1.7%Here's Why - MarketBeat
Pfizer Inc. stock outperforms competitors despite losses on the day - MarketWatch
Pfizer Inc’s Next Growth Bet Is India. Investors Are Still Waiting For Proof - TechStock²
Pfizer Inc. stock (US7170811035): Q1 2026 beat, new products lift revenue while COVID business stays - AD HOC NEWS
Duavee by Pfizer, Inc - Pharmacy Times
Pfizer Refines PF-07799933 Dosing in New Phase 1 Food-Effect Study - TipRanks
Mubadala Investment dissolves share stake in Pfizer, Ford Motor, Walt Disney - marketscreener.com
Mubadala Investment Dissolves Share Stake In Pfizer, Ford Motor, Walt Disney - TradingView
Mesirow Financial Investment Management Inc. Cuts Holdings in Pfizer Inc. $PFE - MarketBeat
5 Must-Read Analyst Questions From Pfizer’s Q1 Earnings Call - Yahoo Finance
AustralianSuper Pty Ltd Acquires 671,258 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer, Inc. Stock 12‑Month Price Target Cut to $28.88, Implies 12% Upside - TradingView
PFIZER INC HUGE TARGET | PFE STOCK NEWS (jCUEslO3m8) - fathomjournal.org
Amid COVID-19 Global Pandemic, The Pfizer Foundation Helps IRC Pursue Urgent Expansion of Health Access in Humanitarian Settings - Pfizer
Pfizer’s Prazosin Site-Transfer Trial Signals Quiet but Important Supply-Chain Progress - TipRanks
Pfizer stock (US7170811035): Q1 earnings beat with revenue growth and 2026 guidance - AD HOC NEWS
Jim Cramer on Pfizer: “Pfizer Does Not Have Any Earnings Momentum” - Insider Monkey
Pfizer Just Locked In Its Next 5 Years of Growth -- Here's How - Yahoo Finance
Comirnaty COVID-19 Vaccine - AD HOC NEWS
Pfizer's Turnaround Is Taking Shape (NYSE:PFE) - Seeking Alpha
PFE Stock Declines Post Q1 Beat: Book Profits or Stay Invested? - TradingView
PFE Stock Outlook 2026: Is Pfizer a Smart Investment Right Now? - sebd.in
The Zacks Analyst Blog Meta, Pfizer, Salesforce and Smith-Midland - Yahoo Finance Singapore
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, ArvinasHas The Bull Case Changed? - Yahoo Finance
Pfizer Hemophilia Drug Win In Europe Adds Weight To Undervalued Thesis - simplywall.st
European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors - BioSpace
Get to Know Our Breakthrough Fellows! - Pfizer
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pfizer Inc Azioni (PFE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
0.07%
0.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):